Lung Cancer

Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the management of immune-related adverse events (irAEs) in patients with lung cancer.

Janakiraman Subramanian, MD, medical oncologist, director of Thoracic Oncology, Center for Precision Medicine, Saint Luke’s Cancer Institute, discusses the IMpower131 trial in advanced squamous non–small cell lung cancer (NSCLC).

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses the improved outlook for patients with lung cancer.

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses mechanisms of resistance in the treatment of patients with lung cancer.

Lurbinectedin as monotherapy was found to elicit responses in patients with relapsed small cell lung cancer, meeting the primary endpoint of a phase II trial by both investigator review and an independent review committee.

PD-L1 testing, while an imperfect biomarker, is the key determinant of frontline immunotherapy selection in the NCCN guidelines for non–small cell lung cancer.

Timothy Saettele, MD, interventional pulmonologist at Saint Luke’s Hospital, discusses the benefits of using bronchoscopies in patients with non–small cell lung cancer (NSCLC).

Matthew A. Gubens, MD, MS, discusses an update to the NCCN Guidelines regarding patients with PD-L1 non–small cell lung cancer.

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses personalizing therapy in the treatment of patients with lung cancer.

Elaine Shum, MD, medical oncologist, NYU Langone’s Perlmutter Cancer Center, discusses the use of dacomitinib in the treatment of patients with EGFR-positive non–small cell lung cancer.

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses traditional roles of radiation therapy in the treatment of patients with lung cancer.

The FDA has granted an approval to the combination of atezolizumab with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.

Eric Vallieres, MD, medical director, Division of Thoracic Oncology, Swedish Cancer Institute, discusses postoperative quality of life in patients with lung cancer.

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, at University of Miami Miller School of Medicine, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the promise of immunotherapy in the treatment of patients with stage III unresectable non–small cell lung cancer.

The European Commission has approved pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel for the frontline treatment of patients with metastatic squamous non–small cell lung cancer.

Heather Wakelee, MD, associate professor of medicine, Stanford University Medical Center, discusses the importance of next-generation sequencing testing in the treatment of patients with non–small cell lung cancer.

The combination of ramucirumab and erlotinib significantly improved progression-free survival compared with placebo and erlotinib as a frontline treatment for patients with metastatic EGFR-mutant non–small cell lung cancer, meeting the primary endpoint of the RELAY trial (NCT02411448).

Naiyer A. Rizvi, MD, highlights the progress made with immunotherapy in patients with NSCLC and shed light on where further research needs to go to move the needle forward.

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses considerations for managing immune-related adverse events in patients with non–small cell lung cancer.

Sukhmani Padda, MD, assistant professor of medicine, Stanford University Medical Center, member, Stanford Cancer Institute, discusses novel combinations in the treatment of patients with EGFR-positive non–small cell lung cancer.

The European Commission has approved and granted marketing authorization to the frontline combination of atezolizumab, bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic, nonsquamous non–small cell lung cancer.

Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the utility of liquid biopsies in lung cancer.

Mohammad Jahanzeb, MD, shares the challenges of real-world eligibility for immunotherapy in lung cancer and beyond.

Heather Wakelee, MD, associate professor of medicine, Stanford University Medical Center, discusses unmet needs for immunotherapy in the treatment of patients with non–small cell lung cancer.